F2G Ltd
The Manchester Incubator Building
Grafton Street
Manchester
M139XX
United Kingdom
Tel: 44-0-161-606-7250
Fax: 44-0-161-606-7251
Website: http://www.f2g.com/
About F2G Ltd
F2G is an established UK Biotech focusing on the discovery and development of novel drugs to treat life threatening fungal diseases. Fungal infection typically affects the immune-compromised patient where mortality rates are often very high. This patient population is increasing year by year due to increased cases of cancer, organ transplants and the use of potent medicines that affect the immune system. As a result serious fungal infections continue to increase. The focus at F2G is to serve the current unmet medical need by developing drugs that target the most difficult to treat fungi, especially those with the highest mortality rates. Through its proprietary genomics technology and antifungal screening activities F2G has identified a number of novel chemical series with potent antifungal activity. These novel series form the basis of the F2G development pipeline. Currently F2G is advancing its F3 series of anti mould compounds. This is a novel class of antifungal agent, which acts through a completely new mechanism different from all currently marketed drugs. The F3 series displays highly potent activity against clinically relevant aspergilli and many other important pathogenic moulds. F2G has a dedicated team of experienced scientists from a wide variety of research and drug development backgrounds supported by an experienced management group with many years experience of drug development within the Pharmaceutical industry.YEAR FOUNDED:
1998
LEADERSHIP:
CEO: Ian Nicholson
30 articles about F2G Ltd
-
F2G and Shionogi Present Full Data Set from Pivotal Phase 2b Study at Trends in Medical Mycology (TIMM) 2023 Demonstrating Positive Therapeutic Responses in Patients with Invasive Fungal Infections Treated with Oral Olorofim
10/21/2023
F2G Ltd. and Shionogi & Co., Ltd., announced full results from the pivotal Phase 2b open-label study of olorofim in patients with proven invasive fungal infections or probable pulmonary invasive aspergillosis and limited or no treatment options.
-
F2G Receives Complete Response Letter from FDA for New Drug Application for Olorofim for The Treatment of Invasive Fungal Infections; Plans Resubmission With Additional Data and Analyses
6/19/2023
F2G Ltd. today announced that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) regarding the New Drug Application (NDA) for olorofim, an investigational antifungal, for the treatment of invasive fungal infections in patients who have limited or no treatment options.
-
At the World Vaccine Congress, antimicrobial resistance as a global health crisis grabbed top billing.
-
F2G to Present at Biotech Showcase™ 2023
1/5/2023
F2G Ltd. today announced that the Company’s chief executive officer, Francesco Lavino will provide a corporate overview at Biotech Showcase™ 2023 taking place in San Francisco, California, from January 9-11, 2023.
-
F2G Announces FDA Filing Acceptance of New Drug Application for Olorofim for the Treatment of Invasive Fungal Infections
12/19/2022
F2G Inc. announced that the U.S. Food and Drug Administration has accepted for filing its New Drug Application for olorofim for the treatment of invasive fungal infections in patients who have limited or no treatment options.
-
F2G to Present Interim Results from Phase 2B Open Label Study of Olorofim in Invasive Fungal Infections at IDWeek 2022
10/13/2022
F2G Ltd today announced that it will present new clinical data in three oral presentations and two poster presentations at IDWeek 2022, to be held in Washington, D.C. from October 19-23, 2022.
-
BioSpace Movers & Shakers, Jan. 28
1/28/2022
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Olorofim is in a Phase IIb study that focuses on rare and resistant life-threatening invasive fungal infections, such as invasive aspergillosis (including azole-resistant strains), scedosporiosis, lomentosporiosis, fusariosis, scopulariopsosis and coccidioidomycosis.
-
F2G Receives US FDA Breakthrough Therapy Designation for Olorofim
11/11/2019
In Phase 2b development for the treatment of life-threatening fungal infections
-
F2G Receives European Orphan Drug Designation For Its Lead Candidate F901318
1/9/2017
-
F2G Announces The Appointment Of John H. Rex, MD, FACP To The Position Of Chief Medical Officer
12/5/2016
-
F2G Announces Publication Of Initial F901318 Data In Scientific Journal PNAS
10/26/2016
-
F2G Announces The Appointment Of Ralf Schmid To The Position Of Chief Financial Officer
7/11/2016
-
Backed by Novartis AG and Novo Nordisk A/S, UK Biotech F2G Bags $60 Million
6/20/2016
-
F2G Ltd Release: Adaptive Pathways
12/1/2015
-
F2G License Cresset’s Forge To Complement Successful Consulting Projects
4/8/2015
-
F2G Ltd, The UK-Based Antifungal Drug Discovery And Development Company, Today Announced A Major Funding Award From The Technology Strategy Board’s Biomedical Catalyst
9/9/2014
-
F2G Ltd, The UK-Based Antifungal Drug Discovery And Development Company, Today Announces Commencement Of A Phase 1 Single Ascending Dose Study Of A Novel Antifungal Agent, F901318.
9/2/2014
-
F2G Ltd and the University of Manchester Announce a New €6.1 Million Project to Develop New Antifungal Agents to Treat Resistant Fungal Infections
6/25/2013
-
F2G Ltd Appoints Ian Nicholson as CEO
3/18/2013